Century Therapeutics (IPSC) FY Conference Transcript

Summary of Century Therapeutics Conference Call Company Overview - Company: Century Therapeutics - Ticker: IPSC (NASDAQ) - Focus: Development of next-generation allogeneic cell therapies from programmable induced pluripotent stem cells (iPSCs) for autoimmune diseases and cancer [1][2] Core Technology and Pipeline - Core Technology: AlloVision technology, which enables the engineering of iPSC-derived cell therapies [2][5] - Key Programs: - Century 308: CD19 targeting CD4/CD8 alpha-beta CARiT cell therapy, currently in IND-enabling studies for B-cell-mediated diseases [3][5] - Century 101: CAR INK therapy targeting CD19, currently in clinical trials for autoimmune diseases [18][19] Clinical Development and Milestones - Cash Runway: Estimated to extend into Q4 2027, covering key clinical milestones [5] - Clinical Trials: - Century 101: In two Phase I trials for systemic lupus erythematosus (SLE), lupus nephritis, myositis, and systemic sclerosis [18][19] - Century 308: Expected to enter the clinic next year [5][18] Market Opportunity - Autoimmune Disease Market: Significant unmet medical need with tens of thousands of addressable patients in the U.S. for B-cell-mediated diseases [20][21] - CAR T Therapy Market: Current approved CAR T therapies have close to $5 billion in worldwide sales, but access remains a challenge with fewer than 30% of eligible patients receiving treatment [11][20] AlloVision Technology - Immune Evasion: AlloVision technology involves genetic edits to enhance the persistence of allogeneic cells and reduce rejection by the immune system [6][7] - Holistic Protection: AlloVision 5.0 includes multiple genetic modifications to protect against various immune rejection mechanisms [8][9] Preclinical and Clinical Data - Century 308: Demonstrated comparable functionality to primary T cells in preclinical studies, including IL-2 secretion and tumor control in mouse models [13][17] - Century 101: Established a safe and well-tolerated dose with effective B-cell depletion observed in clinical trials [22][23] Conclusion - Future Outlook: Century Therapeutics aims to leverage its iPSC platform and AlloVision technology to create impactful therapies for patients with severe diseases, with a focus on delivering clinical data throughout 2025 [24]